Search

Uptake of CAR T cell therapy in Europe

Feb 05 2019 Posted in Advocacy news Tagged CAR T

Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.

Read more

Hematopoietic stem cells: New results to be presented at the 18th Congress of the EHA

During ageing, this fine-tuned regulatory network may become altered, leading to abnormal HSC regulation. The functional quality of HSCs decreases with age partly due to an accumulation of damaged DNA, leading to an increased incidence of hematological malignancies.

Read more

Policy & advocacy

At the core of EHA’s advocacy efforts are four priority themes. For each of these themes, the main messages and recommendations directed at EU institutions and other stakeholders have been written down in a Position Paper.

Read more

EHA has joined the European Cancer Organisation - a perfect match on objectives and prioritization

The European Hematology Association (EHA) has joined the European Cancer Organisation, a not-for-profit federation of organizations working in cancer at the European level.

Read more

Position of EHA on the Harmonization of Training and Education in Europe

 

The challenge
Education and training are largely national competencies.

Read more

COVID-19 Expert opinions

Expert opinions for hematologists in COVID-19 crisis
COVID-19, caused by SARS-CoV-2, is expected to be a devastating infection in many patients with hematologic diseases.

Read more